Press Release - 2/21/26
USGinger and Fenton Woods Laboratories Execute 5-Year Master Service Agreement to Study 8-Year "Metabolic Stasis" in California TurmericWalnut Creek, CA — February 21, 2026 — USGinger is proud to announce the formal execution of a five-year Master Service Agreement (MSA) with Fenton Woods Laboratories (FWL), effective February 19, 2026. This landmark partnership aims to explore the therapeutic potential and pharmaceutical applications of USGinger’s proprietary 2018 turmeric harvest, which has achieved an unprecedented 8-year shelf life in a state of metabolic stasis.
A New Benchmark in Botanical StabilityWhile the global spice industry struggles with "potency drift" and regional mold failures, USGinger’s 2018 Merced, CA, crop has demonstrated remarkable chemical resilience. Recent analysis (CoA #USG-2018Q5L2) confirms that after eight years, the rhizomes maintain:•Total Metabolic Stasis: Stability in all three major curcuminoids, with results from 2023 to 2026 showing no significant degradation.•Ultra-Low Moisture (2.1%): A processing milestone that has effectively neutralized the fungal risks currently plaguing other California-grown turmeric.•"California Clean" Purity: Lead (Pb) levels at an exceptional 0.323 ppb, making it a primary candidate for high-sensitivity therapeutic formulations.Joint Research Objectives (2026–2031)Under the new MSA, USGinger and Fenton Woods Laboratories will initiate a series of longitudinal studies focusing on: Therapeutic Predictability: Validating the use of "Aged Stasis" turmeric as a standardized raw material for pharmaceutical drug delivery.2.Microbial Defense Mapping: Quantifying the environmental resistance of USGinger’s 2.1% moisture processing method against regional pathogens.3.Bio-Active Retention: Studying the long-term survival of secondary metabolites in low-oxygen, low-moisture environments.
ManagementCommentary:
Fenton Woods Laboratories sees the immense potential in our products for the therapeutic fields," says the USGinger leadership team. "This 5-year commitment validates our belief that processing and storage methods have outweighed raw harvest potency. We are no longer just selling a crop; we are providing a guaranteed, non-drifting chemical signature that the pharmaceutical industry has been seeking for decades."________________________________________
Investor & Media Contact For technical data or to inquire about partnership opportunities in our ongoing stability studies, please visit:www.usginger.com or sales@usginger.com
II. Stability Metrics for Therapeutic Formulation MetricResult (8-Year Milestone)Therapeutic Significance Metabolic StateStasis (Non-Drifting)Eliminates "potency drift" in long-term drug storage. (p. 1) Curcuminoids3-Complex PresentValidates the survival of secondary metabolites (Metabolite 1 & 2). (p. 1) Moisture2.1% (Ultra-Low)Prevents enzymatic degradation and fungal proliferation. (p. 1) Lead (Pb)0.323 ppbFar below FDA "Clean Label" targets; ideal for sensitive patients. (p. 1) Microbial1.7 x 10⁵ CFU/gProven safety profile without irradiation or chemicals. (p. 2) III. Therapeutic Potential Under the 5-Year MSA Fenton Woods Laboratories' commitment suggests three major "High-Potential" research avenues for this specific lot: 1.Excipient-Grade Stability: Using the 2018 root as a standardized "Base Carrier" that will not react with or degrade added active pharmaceutical ingredients (APIs).
